LEADING THE WAY IN ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT
Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of promising treatments for the future.
The content listed here is representative of Taiho Oncology Inc. sponsored/co-sponsored studies, aligned with latest information available in http://clinicaltrials.gov.
For a listing of Taiho studies globally, please see the following.
- Phase 1
- Phase 2
- Phase 3
All data is current as of November 2022.
* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country's Regulatory Authority. In addition, the clinical efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.
1 LONSURF® (trifupridine and tipiracil) tablets, is FDA approved for the treatment of adult patients with:
- metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
- metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
2 LYTGOBI® (futibanib) is FDA approved for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.